UNITED THERAPEUTICS CORP DEL's ticker is UTHR and the CUSIP is 91307C102. A total of 335 filers reported holding UNITED THERAPEUTICS CORP DEL in Q4 2014. The put-call ratio across all filers is 0.98 and the average weighting 0.4%.
About UNITED THERAPEUTICS CORP DEL
United Therapeutics Corp Del is a biotechnology company that specializes in the development and commercialization of innovative therapies for patients with chronic and life-threatening diseases. The company's focus is on pulmonary arterial hypertension (PAH), a condition that affects the blood vessels in the lungs and can lead to heart failure.
United Therapeutics has a strong pipeline of products in development, including oral and inhaled therapies for PAH, as well as treatments for other diseases such as neuroblastoma and sickle cell disease. The company's flagship product, Remodulin, is an injectable therapy for PAH that has been on the market for over 20 years and has helped thousands of patients.
In recent years, United Therapeutics has also been investing in digital health technologies to improve patient outcomes and reduce healthcare costs. The company has developed a mobile app called "PAH Pathways" that helps patients manage their condition and track their symptoms, as well as a telemedicine platform that allows doctors to remotely monitor patients.
Despite the challenges posed by the COVID-19 pandemic, United Therapeutics has continued to make progress in its research and development efforts. The company recently announced positive results from a Phase 3 clinical trial of its oral therapy for PAH, and is also exploring the potential of gene therapy for the treatment of rare diseases.
Overall, United Therapeutics Corp Del is a company with a strong track record of innovation and a commitment to improving the lives of patients with serious illnesses. Investors looking for exposure to the biotech sector may want to consider adding this stock to their portfolio.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,131,665 | +31.1% | 9,831 | -5.4% | 0.02% | +31.2% |
| Q1 2024 | $2,387,939 | +4.9% | 10,395 | +0.4% | 0.02% | -5.9% |
| Q4 2023 | $2,277,181 | +6.1% | 10,356 | +9.0% | 0.02% | -5.6% |
| Q3 2023 | $2,146,668 | -57.1% | 9,504 | -58.0% | 0.02% | -53.8% |
| Q2 2023 | $4,998,884 | +8.7% | 22,645 | +10.3% | 0.04% | 0.0% |
| Q1 2023 | $4,597,451 | +80528.7% | 20,528 | +0.1% | 0.04% | -18.8% |
| Q4 2022 | $5,702 | -99.8% | 20,503 | +13.6% | 0.05% | +26.3% |
| Q3 2022 | $3,778,000 | -10.6% | 18,046 | +0.6% | 0.04% | -15.6% |
| Q2 2022 | $4,226,000 | +42.7% | 17,934 | +8.7% | 0.04% | +55.2% |
| Q1 2022 | $2,961,000 | -8.2% | 16,506 | +10.5% | 0.03% | -14.7% |
| Q4 2021 | $3,227,000 | +17.9% | 14,932 | +0.7% | 0.03% | +6.2% |
| Q3 2021 | $2,738,000 | +2.3% | 14,831 | -0.6% | 0.03% | +6.7% |
| Q2 2021 | $2,677,000 | +7.7% | 14,923 | +0.4% | 0.03% | -3.2% |
| Q1 2021 | $2,486,000 | +10.3% | 14,860 | +0.1% | 0.03% | -3.1% |
| Q4 2020 | $2,253,000 | +56.7% | 14,840 | +4.3% | 0.03% | +14.3% |
| Q3 2020 | $1,438,000 | +27.6% | 14,234 | +52.9% | 0.03% | +33.3% |
| Q2 2020 | $1,127,000 | +15.1% | 9,311 | -9.8% | 0.02% | -4.5% |
| Q1 2020 | $979,000 | +43.5% | 10,324 | +33.4% | 0.02% | +83.3% |
| Q4 2019 | $682,000 | +10.7% | 7,740 | +0.2% | 0.01% | +9.1% |
| Q3 2019 | $616,000 | +2.2% | 7,721 | +0.0% | 0.01% | +10.0% |
| Q2 2019 | $603,000 | -33.3% | 7,720 | +0.2% | 0.01% | -37.5% |
| Q1 2019 | $904,000 | +8.5% | 7,703 | +0.7% | 0.02% | 0.0% |
| Q4 2018 | $833,000 | -26.4% | 7,648 | -13.6% | 0.02% | 0.0% |
| Q3 2018 | $1,132,000 | -14.9% | 8,851 | -24.7% | 0.02% | -11.1% |
| Q2 2018 | $1,330,000 | +1.5% | 11,753 | +0.8% | 0.02% | 0.0% |
| Q1 2018 | $1,310,000 | +40.3% | 11,658 | +84.7% | 0.02% | +38.5% |
| Q4 2017 | $934,000 | +25.7% | 6,312 | -0.4% | 0.01% | +18.2% |
| Q3 2017 | $743,000 | -12.9% | 6,337 | -3.6% | 0.01% | -15.4% |
| Q2 2017 | $853,000 | -4.0% | 6,576 | +0.1% | 0.01% | -13.3% |
| Q1 2017 | $889,000 | -1.3% | 6,568 | +4.6% | 0.02% | -11.8% |
| Q4 2016 | $901,000 | +18.7% | 6,280 | -2.3% | 0.02% | +13.3% |
| Q3 2016 | $759,000 | -16.6% | 6,430 | -25.1% | 0.02% | -11.8% |
| Q2 2016 | $910,000 | +0.8% | 8,589 | +5.9% | 0.02% | -10.5% |
| Q1 2016 | $903,000 | -56.4% | 8,107 | -38.7% | 0.02% | -56.8% |
| Q4 2015 | $2,072,000 | +20.1% | 13,229 | +0.6% | 0.04% | +7.3% |
| Q3 2015 | $1,725,000 | -25.7% | 13,147 | -1.6% | 0.04% | -2.4% |
| Q2 2015 | $2,323,000 | +10.6% | 13,354 | +9.6% | 0.04% | +10.5% |
| Q1 2015 | $2,100,000 | +59.1% | 12,179 | +19.5% | 0.04% | +100.0% |
| Q4 2014 | $1,320,000 | +56.4% | 10,191 | +55.4% | 0.02% | +46.2% |
| Q3 2014 | $844,000 | +55.4% | 6,560 | +6.9% | 0.01% | +62.5% |
| Q2 2014 | $543,000 | -11.0% | 6,136 | -5.4% | 0.01% | -11.1% |
| Q1 2014 | $610,000 | -16.8% | 6,484 | -0.0% | 0.01% | -25.0% |
| Q4 2013 | $733,000 | +42.6% | 6,485 | -0.5% | 0.01% | +33.3% |
| Q3 2013 | $514,000 | +18.7% | 6,519 | -0.8% | 0.01% | +28.6% |
| Q2 2013 | $433,000 | – | 6,573 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 201,612 | $36,171,000 | 12.47% |
| Avoro Capital Advisors LLC | 3,030,000 | $543,612,000 | 9.92% |
| Palo Alto Investors LP | 653,079 | $117,169,000 | 9.06% |
| Consonance Capital Management LP | 24,563 | $4,407,000 | 7.48% |
| Soleus Capital Management, L.P. | 305,850 | $54,873,000 | 7.08% |
| Eagle Health Investments LP | 159,238 | $28,569,000 | 7.04% |
| Summit Street Capital Management, LLC | 37,805 | $6,783,000 | 4.10% |
| Iron Triangle Partners LP | 190,073 | $34,101,000 | 4.06% |
| Eversept Partners, LP | 292,234 | $52,429,702 | 4.03% |
| DG Capital Management, LLC | 108,955 | $19,548,000 | 3.91% |